使用深度生成模型对临床前阿尔茨海默病的现实世界预测
Uiwon Hwang1, Sung-Woo Kim2, Dahuin Jung3
1Division of Digital Healthcare, Yonsei University, Wonju, 26493, Republic of Korea.
Artificial intelligence in medicine
|October 2, 2023
概括
这项研究引入了一种深度生成模型,以非侵入的方式预测阿尔茨海默病的粉样蛋白阳性. 该模型使用MRI和认知数据准确识别早期疾病指标,优于现有方法.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 生物医学诊断 生物医学诊断
背景情况:
- 粉样蛋白阳性是阿尔茨海默病 (AD) 的关键早期标志物.
- 目前用于粉样蛋白状况的诊断方法可能是侵入性的和昂贵的.
- 在临床前阶段预测粉样蛋白阳性对于及时干预至关重要.
研究的目的:
- 开发和验证一个深度生成模型,用于预测认知正常个体的粉样蛋白阳性.
- 使用非侵入性代理措施,如结构性MRI,人口统计和认知分数进行预测.
- 通过可解释性和适应性,提高深度学习模型的临床可翻译性.
主要方法:
- 用一个深度生成模型来预测粉样蛋白阳性.
- 该模型利用结构性MRI扫描,人口统计变量和认知得分作为输入特征.
- 使用接收器操作特征曲线 (AUROC) 下的面积来评估性能.
主要成果:
- 深度生成模型实现了0.8609的AUROC,超过了之前的研究和标准机器学习方法.
- 该模型在处理不完美的数据集 (缺失的数据,不平衡的类) 中表现出了稳健性.
- 发现的关键预测特征包括侧叶,后叶和APOE ε4等位基因.
结论:
- 深度生成模型为临床前阿尔茨海默氏症诊断提供了一种具有成本效益,非侵入性和准确的方法.
- 该模型适应不同临床数据和标准的适应性支持其在现实世界中的适用性.
- 这种方法解决了临床翻译的关键要求,包括可转移性和可解释性.
相关概念视频
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


